D'AMICO ALEX enters CYTOSORBENTS CORP with 210K shares plus derivative instruments
Holding both equity and derivatives at entry signals strong long-term conviction in the company.
Direct Derivatives
Filed: 8/15/2023ACC: 0001104659-23-092058
Officer· Chief Financial Officer
Since Aug 2023
210K
Baseline shares
100% direct
210K
Direct ownership
1 position
285K
Derivative underlying
2 instruments
1
Security positions
All direct
Non-Derivative Holdings1
Common Stock
DirectShares owned210K
Total
210K direct210K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 210K | Direct |
| Total | 210K | 210K direct |
Derivative Holdings2
Stock Option (right to buy)
DirectUnderlying security
Common Stock
Underlying shares
70K
Shares owned
N/A
Exercise price
3.48
Expiration
—
Exercise window
—
Stock Option (right to buy)
DirectUnderlying security
Common Stock
Underlying shares
215K
Shares owned
N/A
Exercise price
3.48
Expiration
—
Exercise window
—
Total
Underlying
285K
Owned
0.00
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Common Stock | 3.48 | — | — | 70K | N/A |
| Stock Option (right to buy) Direct | Common Stock | 3.48 | — | — | 215K | N/A |
| Total | 285K | 0.00 | ||||